E-Newsletter - September 2021
	Message From the Group Chair
	 
	 ChaNGE IN VENUE ::
ChaNGE IN VENUE ::
	2021 ALLIANCE FALL GROUP MEETING
I am sure that you are all following with concern the current status of COVID-19 infection in our communities. It is now clear that although vaccinated individuals are mostly protected from serious disease, they can develop an infection that can be transmitted to others. This raises serious concerns for all of us who interact frequently with vulnerable patients. Therefore, although we all hoped to return to in-person Alliance meetings this fall because travel significantly increases the risk of infection, we have decided that the November Alliance Group Meeting will be held in an all-virtual format.
I can't say enough how much I admire all of the wonderful Alliance researchers who have continued our important work throughout the many challenges of the past 18 months. In many ways, we have been more productive than ever, enrolling patients, designing and launching new studies, and managing complex research operations disrupted by changes in our health system. Your selfless dedication to making the world better by tackling the challenges of cancer is truly inspiring.
I look forward to seeing all of you virtually in November, and hopefully in person in spring, 2022.
With sincere gratitude,

For other articles in this issue of the Alliance E-News newsletter, see below.
- Message From the Group Chair - Monica M. Bertagnolli, MD
- Registration Now Open - 2021 Alliance Fall Virtual Group Meeting
- Alliance Expresses Gratitude to Committee Chairs Ending Terms
- Alliance Welcomes New Committee Leaders
- NCI NCORP Honors Two Alliance Members
- 
			Spotlight on Alliance Trials
 Ten Currently Active Alliance Cancer Control Program/NCORP Research Base Trials
 Alliance A171901 - Lung Cancer
 Alliance A191901 - Endocrine Therapy Adherence
 Alliance A211102 - Testing for Atypia
 Alliance A211601 - Mammographic Breast Density
 Alliance A221702 - Axillary Reverse Mapping
 Alliance A221805 - Peripheral Neuropathy
 Alliance A222001 - Reducing Hot Flashes in Men
 Alliance A231601CD - Improving Surgical Care/Outcomes (OPIT-Surg)
 Alliance A231701CD - Shared Breast Cancer Surgery Decision Making
 Alliance A231901CD - Patient-Centered Communication in Breast Cancer
 
 Four Recently Activated Alliance NCTN Trials
 Alliance A021901 - Bronchial Neuroendocrine Tumors
 Alliance A051902 - Peripheral T-cell Lymphoma
 Alliance A031902 - Metastatic Castration-Resistance Prostate Cancer (CASPAR)
 Alliance A011801 - HER2-Positive Breast Cancer (CompassHER2)
 
 Closed to Accrual: Alliance A221505 (RT CHARM)
- 
			Alliance Funding Opportunities
 Daniel J. Sargent, PhD Memorial Fellowship in Innovative Clinical Trial Design and Methods Award
- 
			Alliance in the News
 Patient Perspective in Clinical Trials – Alliance Patient Advocate Julie Krause Interview
 Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
 Patient Perspective on Clinical Trials - Alliance Patient Advocate Julie Krause
 Impact of the COVID-19 Pandemic on Clinical Trials
 Combining Tumor Deposits with the Number of Lymph Node Metastases to Improve the Prognostic Accuracy in Stage III Colon Cancer: A Post Hoc Analysis of the CALGB/SWOG 80702 Phase III Study (Alliance)
 New ECU, Vidant Partnership Provides Access to Clinical Trials for Rare Cancers
 Celecoxib Provides No Survival Benefit for Patients with Stage III Colon Cancer
 Disparities in Older Adult Accrual to Cancer Trials: Analysis from the Alliance for Clinical Trials in Oncology (A151736)


